MedTrace Logo

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

NCT03488485 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50000

Last updated 2019-06-14

No results posted yet for this study

Summary

Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients. The Mukh Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) was launched in June 2016 to provide free treatment to all CHC aiming to eliminate HCV from Punjab. The study assessed the feasibility of decentralized care and efficacy and safety of 12 or 24 weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) ± ribavirin (RBV) in the treatment of CHC patients in a public health care setting.

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Direct Acting Antivirals

DAAs given in patients with viremic chronic hepatitis C

Sponsors & Collaborators

  • Directorate of Health and Family Welfare, Punjab

    collaborator OTHER

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-18
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488485 on ClinicalTrials.gov